ARS Pharmaceuticals, Inc. SPRY Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s retained earnings?
- ARS Pharmaceuticals, Inc. (SPRY) reported retained earnings of -$355.22M in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s retained earnings changed year-over-year?
- ARS Pharmaceuticals, Inc.'s retained earnings decreased by 125.9% year-over-year, from -$157.25M to -$355.22M.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s retained earnings?
- Over 5 years (2020 to 2025), ARS Pharmaceuticals, Inc.'s retained earnings has grown at a 24.9% compound annual growth rate (CAGR), from -$96.73M to -$294.6M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.